Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
Neelima DenduluriMark R SomerfieldMariana Chavez-MacGregorAmy H ComanderZoneddy DayaoAndrea EisenRachel A FreedmanRagisha GopalakrishnanStephanie L GraffMichael J HassettTari A KingGary H LymanGillian Rice MaupinRaquel NunesCheryl L PerkinsMelinda L TelliMaureen E TrudeauAntonio C WolffSharon H GiordanoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Patients with HER2-positive breast cancer with pathologic invasive residual disease at surgery after standard preoperative chemotherapy and HER2-targeted therapy should be offered 14 cycles of adjuvant T-DM1, unless there is disease recurrence or unmanageable toxicity. Clinicians may offer any of the available and approved formulations of trastuzumab, including trastuzumab, trastuzumab and hyaluronidase-oysk, and available biosimilars.Additional information can be found at www.asco.org/breast-cancer-guidelines.
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- early breast cancer
- metastatic breast cancer
- locally advanced
- minimally invasive
- early stage
- oxidative stress
- coronary artery bypass
- neoadjuvant chemotherapy
- tyrosine kinase
- patients undergoing
- palliative care
- clinical practice
- hyaluronic acid
- coronary artery disease
- radiation therapy
- type diabetes
- recombinant human
- percutaneous coronary intervention
- acute coronary syndrome
- surgical site infection
- breast cancer risk